SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV

A Borghetti; Andrea CALCAGNO; F Lombardi; J Cusato; S Belmonti; A D'Avolio; N Ciccarelli; S La Monica; M Colafigli; V Delle Donne; R De Marco; E Tamburrini; E Visconti; G Di Perri; A De Luca; S Bonora; S Di Giambenedetto

doi:10.1093/jac/dky508

SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV

A Borghetti
, Andrea CALCAGNO
, F Lombardi
, J Cusato
, S Belmonti
, A D'Avolio
, N Ciccarelli
, S La Monica
, M Colafigli
, V Delle Donne
, R De Marco
, E Tamburrini
, E Visconti
, G Di Perri
, A De Luca
, S Bonora
, S Di Giambenedetto

Department of Translational Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs.

Original language	English
Pages (from-to)	1035-1043
Number of pages	9
Journal	Journal of Antimicrobial Chemotherapy
Volume	74
Issue number	4
DOIs	https://doi.org/10.1093/jac/dky508
Publication status	Published - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/jac/dky508

https://hdl.handle.net/11579/216909

Cite this

Borghetti, A., CALCAGNO, A., Lombardi, F., Cusato, J., Belmonti, S., D'Avolio, A., Ciccarelli, N., La Monica, S., Colafigli, M., Delle Donne, V., De Marco, R., Tamburrini, E., Visconti, E., Di Perri, G., De Luca, A., Bonora, S., & Di Giambenedetto, S. (2019). SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. Journal of Antimicrobial Chemotherapy, 74(4), 1035-1043. https://doi.org/10.1093/jac/dky508

@article{c54cb38248a34cc2a899dea669fcbc77,

title = "SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV",

abstract = "Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs.",

author = "A Borghetti and Andrea CALCAGNO and F Lombardi and J Cusato and S Belmonti and A D'Avolio and N Ciccarelli and \{La Monica\}, S and M Colafigli and \{Delle Donne\}, V and \{De Marco\}, R and E Tamburrini and E Visconti and \{Di Perri\}, G and \{De Luca\}, A and S Bonora and \{Di Giambenedetto\}, S",

year = "2019",

doi = "10.1093/jac/dky508",

language = "English",

volume = "74",

pages = "1035--1043",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "4",

}

Borghetti, A, CALCAGNO, A, Lombardi, F, Cusato, J, Belmonti, S, D'Avolio, A, Ciccarelli, N, La Monica, S, Colafigli, M, Delle Donne, V, De Marco, R, Tamburrini, E, Visconti, E, Di Perri, G, De Luca, A, Bonora, S & Di Giambenedetto, S 2019, 'SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV', Journal of Antimicrobial Chemotherapy, vol. 74, no. 4, pp. 1035-1043. https://doi.org/10.1093/jac/dky508

TY - JOUR

T1 - SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV

AU - Borghetti, A

AU - CALCAGNO, Andrea

AU - Lombardi, F

AU - Cusato, J

AU - Belmonti, S

AU - D'Avolio, A

AU - Ciccarelli, N

AU - La Monica, S

AU - Colafigli, M

AU - Delle Donne, V

AU - De Marco, R

AU - Tamburrini, E

AU - Visconti, E

AU - Di Perri, G

AU - De Luca, A

AU - Bonora, S

AU - Di Giambenedetto, S

PY - 2019

Y1 - 2019

N2 - Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs.

AB - Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs.

UR - https://iris.uniupo.it/handle/11579/216909

U2 - 10.1093/jac/dky508

DO - 10.1093/jac/dky508

M3 - Article

SN - 0305-7453

VL - 74

SP - 1035

EP - 1043

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 4

ER -

SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this